Across TCGA pan-cancer cohorts, PACRG-AS3 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated PACRG-AS3 data layer.
The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PACRG-AS3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PACRG-AS3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CESC show a favorable association.
ACC, UVM, and LUSC are the cancer types where PACRG-AS3 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.